Gamma rhythms (~20-70 Hz) are abnormal in mental disorders such as autism and schizophrenia in humans, and Alzheimer's disease (AD) models in rodents. However, the effect of normal aging on these oscillations is unknown, especially for elderly subjects in whom AD is most prevalent. In a first large-scale (236 subjects; 104 females) electroencephalogram (EEG) study on gamma oscillations in elderly subjects (aged 50-88 years), we presented full-screen visual Cartesian gratings that induced two distinct gamma oscillations (slow: 20-34 Hz and fast: 36-66 Hz). Power decreased with age for gamma, but not alpha (8-12 Hz). Reduction was more salient for fast gamma than slow. Center frequency also decreased with age for both gamma rhythms. The results were independent of microsaccades, pupillary reactivity to stimulus, and variations in power spectral density with age. Steady-state visual evoked potentials (SSVEPs) at 32 Hz also reduced with age. These results are crucial for developing gamma/SSVEP-based biomarkers of cognitive decline in elderly.
8 May 2023 in Proceedings of the National Academy of Sciences
Gender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women’s worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women’s brains and provide initial evidence for neuroscience-informed policies for gender equality.
22 November 2017 in Journal of the Indian Institute of Science
Tobacco is commonly co-used with cannabis. This is unfortunate because tobacco co-use exacerbates select clinical consequences associated with cannabis use. Evidence demonstrates that low levels of anandamide, a prominent endocannabinoid, correlate with worse clinical outcomes. Fatty acid amide hydrolase (FAAH) degrades anandamide, and greater FAAH levels may underlie poorer clinical outcomes in people who co-use relative to those who use only cannabis. Therefore, we tested whether tobacco co-use increases FAAH levels beyond those associated with cannabis use alone. Cannabis-using participants (N = 13) were parsed into individuals with daily tobacco use (CT, n = 5) and no current tobacco use (CAN, n = 8). We evaluated group differences in FAAH, quantified using positron emission tomography and [11C]CURB, while controlling for sex and FAAH genotype in the prefrontal cortex, hippocampus, thalamus, sensorimotor striatum, substantia nigra, and cerebellum. A significant group x ROI interaction for [11C]CURB λk3 [F(5, 45)= 3.15, p = 0.016] emerged. Bonferroni-corrected post-hoc tests indicated greater FAAH levels in CT compared to CAN in the substantia nigra (p = 0.023, d=1.54) and cerebellum (p = 0.003, d=1.76), while a trend emerged in the sensorimotor striatum (p = 0.054, d=1.33). Preliminary findings suggest that tobacco co-use is associated with elevated FAAH activity relative to cannabis-only use, which may underlie poorer clinical outcomes associated with co-use.
Background: Thought disorder (TD) is a core feature of severe mental illnesses such as schizophrenia, characterized by disruptions in speech, language, and communication. People with TD face unique barriers that hinder their involvement in research, both as participants and as partners. Their systematic underrepresentation in psychiatric research is driven by pervasive assumptions about their decisional capacity, willingness to participate, and ability to engage in research. This perpetuates a biased evidence base, likely hindering the therapeutic progress toward addressing this core problem. Methods: This review, informed by professional (clinical and research) and lived (bottom-up and phenomenological) experience of TD, examines how flawed assumptions regarding capacity, engagement, and participatory abilities serve as active barriers to inclusion. Results: We argue for a shift toward supported inclusion through tailored capacity assessments, enhanced informed consent procedures, targeted training of research personnel, and systemic institutional practices. Incorporating lived experiences of those with TD as research partners is integral to this approach, fostering co-production of research that is more valid, inclusive, and applicable. Conclusions: Without these inclusion-focused changes, the development of treatments for TD is likely to have very slow progress and a critical segment of the severely unwell population will continue to be underrepresented from the scientific process, undermining both the utility and generalizability of psychiatric research.
Background and Hypothesis: Cognitive impairments are particularly disabling for patients with a psychotic disorder and often persist despite optimization of antipsychotic treatment. Thus, motivating an extension of the research focus on the endocannabinoid system. The aim of this study was to evaluate group differences in brain fatty acid amid hydrolase (FAAH), an endocannabinoid enzyme between first-episode psychosis (FEP), individuals with clinical high risk (CHR) for psychosis and healthy controls (HCs). Furthermore, to test the hypothesis that FAAH is linked with cognition using positron emission tomography (PET). Study Design: We analyzed 80 PET scans with the highly selective FAAH radioligand [11C]CURB, including 30 patients with FEP (6 female), 15 CHR (5 female), and 35 HC (19 female). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Berg Card Sorting Test (BCST) were applied to test cognitive performance. Study Results: There was no difference in FAAH activity between groups (F2, 75 = 0.75, P = .48; Cohen’s f = 0.141; small effect). Overall, there was a difference in the association between groups regarding FAAH activity and the domain visuospatial construction (F2, 72 = 4.67, P = .01; Cohen’s f = .36; medium effect). Furthermore, across the sample, lower FAAH activity was associated with a higher percentage of perseverative responses (F1, 66 = 5.06, P = .03; Cohen’s f = 0.28, medium effect). Conclusions: We report evidence for associations between endocannabinoid alterations in FEP and CHR with specific domains of cognition (visuospatial construction and perseverative response), not overall cognition.